Drug Approval | December 10, 2021
China approves Brii Bio’s antibody combination to neutralise Covid-19
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
The platform’s technology works as a compression algorithm for molecular testing
Gland Pharma believes that they are amongst one of the first to file for this product and may be eligible for 180 days of generic drug exclusivity
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
Leaders in scientific and industrial imaging, Atik Cameras prepares for growth as Dr Panos Kapetanopoulos is promoted to DIrector of Atik Cameras Norwich, UK
Subscribe To Our Newsletter & Stay Updated
